<?xml version="1.0" encoding="iso-8859-1" ?>
<newsitem itemid="136013" id="root" date="1996-10-23" xml:lang="en">
<title>USA: Target Q2 shr profit rises to $0.22.</title>
<headline>Target Q2 shr profit rises to $0.22.</headline>
<dateline>FREMONT, Calif. 1996-10-23</dateline>
<text>
<p>TARGET THERAPEUTICS, INC.</p>
<p>		    CONSOLIDATED STATEMENTS OF OPERATIONS</p>
<p>	    (In thousands, except per share amounts; unaudited)</p>
<p>				 Three months ended  Six months ended</p>
<p>					   September 30,  September 30,</p>
<p>				    1996	 1995     1996     1995</p>
<p> Revenue		     $ 22,044  $ 15,741 $ 44,093 $ 29,645</p>
<p>Costs and expenses:</p>
<p>   Cost of sales		6,725     5,047   13,342    9,392</p>
<p>Research and development</p>
<p>				    4,766     2,819    9,895    5,655</p>
<p>Acquired in-process</p>
<p>    research and development   --	  --   14,000	 --</p>
<p>Selling, general and</p>
<p>    administrative	    6,605     4,632   12,562    8,999</p>
<p>Total costs and expenses</p>
<p>				   18,096    12,498   49,799   24,046</p>
<p>Income/(loss) from operations</p>
<p>				    3,948     3,243  (5,706)    5,599</p>
<p> Interest income, net	   416	 494	791	870</p>
<p> Other income/(loss)	    596	 196	871	511</p>
<p> Minority interest	    (110)	(84)    (358)     (84)</p>
<p>Income/(loss) before   income taxes		  4,850     3,849  (4,402)    6,896</p>
<p>Provision for income taxes</p>
<p>				    1,503     1,149    2,975    2,063</p>
<p> Net income/(loss)	    3,347     2,700  (7,377)    4,833</p>
<p>Net income/(loss)   per share			 .22	 .18    (.50)	.32</p>
<p>Shares used in calculation of net   income/(loss) per share  15,520    15,168   14,825   15,030</p>
<p>NOTE: Q2 ended Sept. 30, 1996 includes a pre-tax gain of $925,000 on the sale of common stock investments, which was used primarily to offset legal costs and equity write-offs in affiliates.</p>
</text>
<copyright>(c) Reuters Limited 1996</copyright>
<metadata>
<codes class="bip:countries:1.0">
  <code code="USA">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1996-10-23"/>
  </code>
</codes>
<codes class="bip:industries:1.0">
  <code code="I37200">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1996-10-23"/>
  </code>
</codes>
<codes class="bip:topics:1.0">
  <code code="C15">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1996-10-23"/>
  </code>
  <code code="C151">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1996-10-23"/>
  </code>
  <code code="CCAT">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1996-10-23"/>
  </code>
</codes>
<dc element="dc.date.created" value="1996-10-23"/>
<dc element="dc.publisher" value="Reuters Holdings Plc"/>
<dc element="dc.date.published" value="1996-10-23"/>
<dc element="dc.source" value="Reuters"/>
<dc element="dc.creator.location" value="FREMONT, Calif."/>
<dc element="dc.creator.location.country.name" value="USA"/>
<dc element="dc.source" value="Reuters"/>
</metadata>
</newsitem>
